Pre-exposure prophylaxis (PrEP) for HIV is effective at decreasing the incidence of HIV infection among men who have sex with men (MSM).1-4 However, since the first PrEP formulation was approved in 2012, rates of other sexually transmitted infections (STIs) have increased in this population as well as in the general population.5,6 More than 2.5 million cases of chlamydia, gonorrhea, and syphilis were reported in the United States between 2020 and 2021.7 When left untreated, STIs can lead to...
